Fluidigm Introduces AccuLift Laser Capture Microdissection System to Advance Translational and Clinical Pathology Research - Seite 2

“LCM has been instrumental in empowering new research breakthroughs across a wide range of different diseases, fueling the development of new diagnostic biomarkers and novel therapies,” said Liotta. “The new AccuLift portfolio developed in collaboration with Fluidigm has the potential to transform digital pathology and accelerate translational and clinical research in the future, especially in immuno-oncology and cancer research. By enabling routine cellular capture down to single-cell resolution with unprecedented precision and efficiency, the new LCM workflow will become a powerful new clinical research tool to advance precision medicine.”

“We are thrilled to introduce the new AccuLift product portfolio to expand our market penetration in pathology research and further expand our leadership position in highly multiplexed tissue biomarker detection,” said Chris Linthwaite, President and CEO of Fluidigm. “LCM sample collection provides a nice complement to our product portfolio supporting DNA, RNA and protein analysis from multiple sample types. In partnership with Dr. Liotta and George Mason University, we have incorporated a wealth of expertise into the design of this exciting new system. We have already received positive early interest from research pathologists in cancer centers, academic medical research institutions, biotech, and pharmaceutical companies, and we see a promising future ahead for AccuLift.”

About Fluidigm
Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.